title: Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
abstract: Patients with relapsed or refractory Hodgkin lymphoma (RR-HL) have poor outcomes. Brentuximab vedotin (BV), an antibody-drug conjugate comprising an anti-CD30 antibody conjugated to the potent anti-microtubule agent, monomethyl auristatin E, induces high tumour responses with moderate adverse effects. In a retrospective study, we describe objective response rates and subsequent allogeneic stem cell transplantation (allo-SCT) in patients with RR-HL treated by BV in a named patient program in two French institutions. Twenty-four adult patients with histologically proven CD30(+) RR-HL treated with BV were included from July 2009 to November 2012. Response to BV treatment was evaluated after four cycles. Eleven patients were in complete response (45.8%), while five patients were in partial response (20.8%), with an overall response rate of 66.6%. Eight patients failed to respond to BV (33.3%). All of the responding patients could receive consolidation treatment after BV: three patients underwent autologous stem cell transplantation (auto-SCT), three patients received a tandem auto-SCT/allo-SCT, nine patients received allo-SCT and one patient was treated with donor lymphocyte infusion. We found no treatment-related mortality at day 100 among the 12 patients who underwent BV following by allogeneic transplantation. With a median follow-up of 20 months (range 10.5-43.2), none of them relapsed or died. BV followed by allo-SCT represents an effective salvage regimen in patients with RR-HL.
authors.affiliation: Department of Hematology, Institut Paoli-Calmettes-Université de la Méditerranée, Marseille, France.
authors.forename: Sylvain
authors.initials: S
authors.lastname: Garciaz
authors.forename: Diane
authors.initials: D
authors.lastname: Coso
authors.forename: Frederic
authors.initials: F
authors.lastname: Peyrade
authors.forename: Sabine
authors.initials: S
authors.lastname: Fürst
authors.forename: Ségolène
authors.initials: S
authors.lastname: Duran
authors.forename: Bruno
authors.initials: B
authors.lastname: Chetaille
authors.forename: Isabelle
authors.initials: I
authors.lastname: Brenot-Rossi
authors.forename: Raynier
authors.initials: R
authors.lastname: Devillier
authors.forename: Angela
authors.initials: A
authors.lastname: Granata
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Réda
authors.initials: R
authors.lastname: Bouabdallah
mesh_terms: D000328:Adult; D000079963:Brentuximab Vedotin; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000378:metabolism; D008214:Lymphocytes / Q000166:cytology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D014057:Tomography, X-Ray Computed; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin
keywords: Hodgkin lymphoma; allogeneic transplantation; brentuximab vedotin